Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Germline loss of function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes.

Nagata Y, Narumi S, Guan Y, Przychodzen BP, Hirsch CM, Makishima H, Shima H, Aly M, Pastor V, Kuzmanovic T, Radivoyevitch T, Adema V, Awada H, Yoshida K, Li S, Sole F, Hanna R, Jha BK, LaFramboise T, Ogawa S, Sekeres MA, Wlodarski MW, Cammenga J, Maciejewski JP.

Blood. 2018 Oct 15. pii: blood-2017-05-787390. doi: 10.1182/blood-2017-05-787390. [Epub ahead of print] No abstract available.

PMID:
30322869
2.

A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines.

Martin Gonzalez J, Baudet A, Abelechian S, Bonderup K, d'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J.

Genesis. 2018 Sep;56(9):e23238. doi: 10.1002/dvg.23238.

PMID:
30010246
3.

Acute myeloid leukemia in very old patients.

Lazarevic VL, Bredberg A, Lorenz F, Ölander E, Antunovic P, Cammenga J, Wennström L, Möllgård L, Deneberg S, Derolf Å, Höglund M, Juliusson G.

Haematologica. 2018 Jun 28. pii: haematol.2018.196691. doi: 10.3324/haematol.2018.196691. [Epub ahead of print] No abstract available.

4.

SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.

Davidsson J, Puschmann A, Tedgård U, Bryder D, Nilsson L, Cammenga J.

Leukemia. 2018 May;32(5):1106-1115. doi: 10.1038/s41375-018-0074-4. Epub 2018 Feb 25. Review.

5.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, Järås M.

Blood Adv. 2017 Oct 18;1(23):2046-2057. doi: 10.1182/bloodadvances.2017006148. eCollection 2017 Oct 24.

6.

Ataxia-pancytopenia syndrome with SAMD9L mutations.

Gorcenco S, Komulainen-Ebrahim J, Nordborg K, Suo-Palosaari M, Andréasson S, Krüger J, Nilsson C, Kjellström U, Rahikkala E, Turkiewicz D, Karlberg M, Nilsson L, Cammenga J, Tedgård U, Davidsson J, Uusimaa J, Puschmann A.

Neurol Genet. 2017 Aug 24;3(5):e183. doi: 10.1212/NXG.0000000000000183. eCollection 2017 Oct.

7.

RUNX1 cooperates with FLT3-ITD to induce leukemia.

Behrens K, Maul K, Tekin N, Kriebitzsch N, Indenbirken D, Prassolov V, Müller U, Serve H, Cammenga J, Stocking C.

J Exp Med. 2017 Mar 6;214(3):737-752. doi: 10.1084/jem.20160927. Epub 2017 Feb 17.

8.

Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms.

Tesi B, Davidsson J, Voss M, Rahikkala E, Holmes TD, Chiang SCC, Komulainen-Ebrahim J, Gorcenco S, Rundberg Nilsson A, Ripperger T, Kokkonen H, Bryder D, Fioretos T, Henter JI, Möttönen M, Niinimäki R, Nilsson L, Pronk CJ, Puschmann A, Qian H, Uusimaa J, Moilanen J, Tedgård U, Cammenga J, Bryceson YT.

Blood. 2017 Apr 20;129(16):2266-2279. doi: 10.1182/blood-2016-10-743302. Epub 2017 Feb 15.

9.

Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Staffas A, Arabanian LS, Wei SY, Jansson A, Ståhlman S, Johansson P, Fogelstrand L, Cammenga J, Kuchenbauer F, Palmqvist L.

Oncogene. 2017 Mar;36(11):1516-1524. doi: 10.1038/onc.2016.318. Epub 2016 Sep 12.

PMID:
27617578
10.

Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis.

Velasco-Hernandez T, Säwén P, Bryder D, Cammenga J.

Stem Cell Reports. 2016 Jul 12;7(1):11-8. doi: 10.1016/j.stemcr.2016.06.002. Epub 2016 Jun 30.

11.

Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.

Jaako P, Ugale A, Wahlestedt M, Velasco-Hernandez T, Cammenga J, Lindström MS, Bryder D.

Leukemia. 2017 Jan;31(1):213-221. doi: 10.1038/leu.2016.159. Epub 2016 Jun 3.

PMID:
27256803
12.

Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.

Lübking A, Vosberg S, Konstandin NP, Dufour A, Graf A, Krebs S, Blum H, Weber A, Lenhoff S, Ehinger M, Spiekermann K, Greif PA, Cammenga J.

Leuk Res Rep. 2015 Oct 17;4(2):72-5. doi: 10.1016/j.lrr.2015.10.001. eCollection 2015.

13.

Small molecule screen identifies differentiation-promoting compounds targeting genetically diverse acute myeloid leukaemia.

Baudet A, Ek F, Davidsson J, Soneji S, Olsson R, Magnusson M, Cammenga J, Juliusson G.

Br J Haematol. 2016 Oct;175(2):342-346. doi: 10.1111/bjh.13851. Epub 2015 Nov 16. No abstract available.

PMID:
26567888
14.

Loss of HIF-1α accelerates murine FLT-3(ITD)-induced myeloproliferative neoplasia.

Velasco-Hernandez T, Tornero D, Cammenga J.

Leukemia. 2015 Dec;29(12):2366-74. doi: 10.1038/leu.2015.156. Epub 2015 Jun 24.

PMID:
26104662
15.

The contrast sensitivity of the newborn human infant.

Brown AM, Lindsey DT, Cammenga JG, Giannone PJ, Stenger MR.

Invest Ophthalmol Vis Sci. 2015 Jan 6;56(1):625-32. doi: 10.1167/iovs.14-14757.

16.

Hematopoietic stem cells are intrinsically protected against MLL-ENL-mediated transformation.

Ugale A, Norddahl GL, Wahlestedt M, Säwén P, Jaako P, Pronk CJ, Soneji S, Cammenga J, Bryder D.

Cell Rep. 2014 Nov 20;9(4):1246-55. doi: 10.1016/j.celrep.2014.10.036. Epub 2014 Nov 13.

17.

HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia.

Velasco-Hernandez T, Hyrenius-Wittsten A, Rehn M, Bryder D, Cammenga J.

Blood. 2014 Dec 4;124(24):3597-607. doi: 10.1182/blood-2014-04-567065. Epub 2014 Sep 29.

18.

Hypoxic induction of vascular endothelial growth factor regulates erythropoiesis but not hematopoietic stem cell function in the fetal liver.

Rehn M, Kertész Z, Cammenga J.

Exp Hematol. 2014 Nov;42(11):941-4.e1. doi: 10.1016/j.exphem.2014.08.002. Epub 2014 Sep 8.

PMID:
25220588
19.

Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.

Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, Lefebvre V, Valk PJ, Delwel R, Hoogenkamp M, Nerlov C, Cammenga J, Saez B, Scadden DT, Bonifer C, Ye M, Tenen DG.

Cancer Cell. 2013 Nov 11;24(5):575-88. doi: 10.1016/j.ccr.2013.09.018. Epub 2013 Oct 31. Erratum in: Cancer Cell. 2014 Feb 10;25(2):257. Diruscio, Annalisa [corrected to Di Ruscio, Annalisa].

20.

Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche.

Miharada K, Karlsson G, Rehn M, Rörby E, Siva K, Cammenga J, Karlsson S.

Ann N Y Acad Sci. 2012 Aug;1266:55-62. doi: 10.1111/j.1749-6632.2012.06564.x. Review.

PMID:
22901256
21.

Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.

Reckzeh K, Bereshchenko O, Mead A, Rehn M, Kharazi S, Jacobsen SE, Nerlov C, Cammenga J.

Leukemia. 2012 Jul;26(7):1527-36. doi: 10.1038/leu.2012.37. Epub 2012 Feb 9.

PMID:
22318449
22.

(H)if blood stem cells gO2 sleep: what can wake them up?

Rehn M, Cammenga J.

Cell Cycle. 2011 Oct 15;10(20):3419-20. doi: 10.4161/cc.10.20.17690. No abstract available.

PMID:
22067652
23.

Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78.

Miharada K, Karlsson G, Rehn M, Rörby E, Siva K, Cammenga J, Karlsson S.

Cell Stem Cell. 2011 Oct 4;9(4):330-44. doi: 10.1016/j.stem.2011.07.016.

24.

Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation.

Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE.

Blood. 2011 Sep 29;118(13):3613-21. doi: 10.1182/blood-2010-06-289207. Epub 2011 Aug 2.

25.

Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche.

Rehn M, Olsson A, Reckzeh K, Diffner E, Carmeliet P, Landberg G, Cammenga J.

Blood. 2011 Aug 11;118(6):1534-43. doi: 10.1182/blood-2011-01-332890. Epub 2011 Jun 13.

26.

Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformation.

Quéré R, Karlsson G, Hertwig F, Rissler M, Lindqvist B, Fioretos T, Vandenberghe P, Slovak ML, Cammenga J, Karlsson S.

Blood. 2011 Jun 2;117(22):5918-30. doi: 10.1182/blood-2010-08-301879. Epub 2011 Apr 6.

27.

High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event.

Quéré R, Andradottir S, Brun AC, Zubarev RA, Karlsson G, Olsson K, Magnusson M, Cammenga J, Karlsson S.

Leukemia. 2011 Mar;25(3):515-26. doi: 10.1038/leu.2010.281. Epub 2010 Nov 30.

28.

Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia.

Reckzeh K, Cammenga J.

Int J Hematol. 2010 May;91(4):557-68. doi: 10.1007/s12185-010-0573-1. Epub 2010 Apr 27. Review.

PMID:
20422469
29.

Hypoxia mediates low cell-cycle activity and increases the proportion of long-term-reconstituting hematopoietic stem cells during in vitro culture.

Eliasson P, Rehn M, Hammar P, Larsson P, Sirenko O, Flippin LA, Cammenga J, Jönsson JI.

Exp Hematol. 2010 Apr;38(4):301-310.e2. doi: 10.1016/j.exphem.2010.01.005. Epub 2010 Feb 4.

PMID:
20138114
30.

HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells.

Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjölund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, Cammenga J, Fredlund E, Kaplan DR, Påhlman S.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16805-10. doi: 10.1073/pnas.0904606106. Epub 2009 Sep 16.

31.

Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage.

Järås M, Johnels P, Agerstam H, Lassen C, Rissler M, Edén P, Cammenga J, Olofsson T, Bjerrum OW, Richter J, Fan X, Fioretos T.

Exp Hematol. 2009 Mar;37(3):367-75. doi: 10.1016/j.exphem.2008.11.003. Epub 2009 Jan 9.

PMID:
19135771
32.

Investigation of C/EBPalpha function in human (versus murine) myelopoiesis provides novel insight into the impact of CEBPA mutations in acute myelogenous leukemia (AML).

Niebuhr B, Iwanski GB, Schwieger M, Roscher S, Stocking C, Cammenga J.

Leukemia. 2009 May;23(5):978-83. doi: 10.1038/leu.2008.332. Epub 2008 Nov 20. No abstract available.

PMID:
19020539
33.

Gatekeeper function of the RUNX1 transcription factor in acute leukemia.

Niebuhr B, Fischer M, Täger M, Cammenga J, Stocking C.

Blood Cells Mol Dis. 2008 Mar-Apr;40(2):211-8. Epub 2007 Oct 24. Review.

PMID:
17920312
34.

Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke.

Thored P, Wood J, Arvidsson A, Cammenga J, Kokaia Z, Lindvall O.

Stroke. 2007 Nov;38(11):3032-9. Epub 2007 Sep 27.

PMID:
17901386
35.

RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.

Cammenga J, Niebuhr B, Horn S, Bergholz U, Putz G, Buchholz F, Löhler J, Stocking C.

Cancer Res. 2007 Jan 15;67(2):537-45.

36.

Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.

Cammenga J.

Leukemia. 2005 Oct;19(10):1719-28. Review.

PMID:
16107893
37.

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.

Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, Stocking C.

Blood. 2005 Dec 1;106(12):3958-61. Epub 2005 Aug 4.

38.

AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.

Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, Zhao H, Valk PJ, Lowenberg B, Nimer SD.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4016-21. Epub 2005 Feb 24.

39.

Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element.

Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD.

Blood. 2003 Dec 15;102(13):4369-76. Epub 2003 Aug 28.

40.

Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells.

Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD.

Blood. 2003 Mar 15;101(6):2206-14. Epub 2002 Oct 24.

41.

Transcription factor fusions in acute leukemia: variations on a theme.

Scandura JM, Boccuni P, Cammenga J, Nimer SD.

Oncogene. 2002 May 13;21(21):3422-44. Review.

42.

Mutations in human cancer: how close should we look?

Cammenga J, Nimer SD.

Leuk Res. 2002 May;26(5):459-60. No abstract available.

PMID:
11916519
43.

The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.

Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD.

Blood. 2002 Jan 1;99(1):15-23.

44.

Molecular biology of leukemia.

Jakubowiak A, Cammenga J, Sokolic R, Alvarez S, Jackson G, Hedvat C, Nimer SD.

Curr Oncol Rep. 2000 Mar;2(2):123-31. Review.

PMID:
11122833
45.

Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines.

Klampfer L, Cammenga J, Wisniewski HG, Nimer SD.

Blood. 1999 Apr 1;93(7):2386-94.

46.

In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes.

Wiesmüller L, Cammenga J, Deppert WW.

J Virol. 1996 Feb;70(2):737-44.

Supplemental Content

Loading ...
Support Center